277 related articles for article (PubMed ID: 22784611)
1. Population pharmacokinetic meta-analysis of intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain.
Kaessner N; Nave R; Roepcke S; Facius A; Lahu G
Int J Clin Pharmacol Ther; 2012 Sep; 50(9):665-77. PubMed ID: 22784611
[TBL] [Abstract][Full Text] [Related]
2. An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects.
Plock N; Facius A; Hartmann L; Baumann S; Nave R
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):495-508. PubMed ID: 23611571
[TBL] [Abstract][Full Text] [Related]
3. Single-dose and multi-dose delivery systems for intranasal fentanyl spray are bioequivalent as demonstrated in a replicate pharmacokinetic study.
Nave R; Connolly SM; Popper L; Lahu G; Schmitt H
Int J Clin Pharmacol Ther; 2012 Oct; 50(10):751-9. PubMed ID: 22943926
[TBL] [Abstract][Full Text] [Related]
4. Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl.
Perelman M; Fisher AN; Smith A; Knight A
Int J Clin Pharmacol Ther; 2013 May; 51(5):349-56. PubMed ID: 23458227
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
[TBL] [Abstract][Full Text] [Related]
6. Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain.
Dietrich E; Gums JG
Ann Pharmacother; 2012 Oct; 46(10):1382-91. PubMed ID: 23012382
[TBL] [Abstract][Full Text] [Related]
7. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.
Mercadante S; Radbruch L; Davies A; Poulain P; Sitte T; Perkins P; Colberg T; Camba MA
Curr Med Res Opin; 2009 Nov; 25(11):2805-15. PubMed ID: 19792837
[TBL] [Abstract][Full Text] [Related]
8. Faster absorption and higher systemic bioavailability of intranasal fentanyl spray compared to oral transmucosal fentanyl citrate in healthy subjects.
Nave R; Schmitt H; Popper L
Drug Deliv; 2013; 20(5):216-23. PubMed ID: 23650968
[TBL] [Abstract][Full Text] [Related]
9. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.
Mercadante S; Prestia G; Adile C; Casuccio A
J Pain; 2014 Jun; 15(6):602-7. PubMed ID: 24561001
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain.
Mercadante S; Vellucci R; Cuomo A; Adile C; Cortegiani A; Valle A; Villari P; Casuccio A
Support Care Cancer; 2015 May; 23(5):1349-54. PubMed ID: 25351457
[TBL] [Abstract][Full Text] [Related]
11. Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study.
Parikh N; Goskonda V; Chavan A; Dillaha L
Clin Ther; 2013 Mar; 35(3):236-43. PubMed ID: 23497761
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain.
Kaasa S; Moksnes K; Nolte T; Lefebvre-Kuntz D; Popper L; Kress HG
J Opioid Manag; 2010; 6(1):17-26. PubMed ID: 20297611
[TBL] [Abstract][Full Text] [Related]
13. Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose.
Nalamachu SR; Parikh N; Dillaha L; Rauck R
J Opioid Manag; 2014; 10(4):247-54. PubMed ID: 25162604
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of intranasal fentanyl spray in cancer patients with breakthrough pain.
Thronæs M; Popper L; Eeg M; Jaatun E; Kvitberg M; Kaasa S
Clin Ther; 2015 Mar; 37(3):585-96. PubMed ID: 25641199
[TBL] [Abstract][Full Text] [Related]
15. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
16. Fentanyl pectin nasal spray for breakthrough cancer pain.
Taylor DR; Gabrail N
Future Oncol; 2012 Feb; 8(2):121-30. PubMed ID: 22335576
[TBL] [Abstract][Full Text] [Related]
17. Fentanyl for breakthrough pain: a systematic review.
Davis MP
Expert Rev Neurother; 2011 Aug; 11(8):1197-216. PubMed ID: 21797660
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers.
Darwish M; Kirby M; Robertson P; Tracewell W; Jiang JG
Clin Ther; 2006 May; 28(5):707-14. PubMed ID: 16861092
[TBL] [Abstract][Full Text] [Related]
19. An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer.
Vissers DC; Lenre M; Tolley K; Jakobsson J; Sendersky V; Jansen JP
Value Health; 2011; 14(2):274-81. PubMed ID: 21402296
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of fentanyl buccal tablet: a pooled analysis and review.
Darwish M; Xie F
Pain Pract; 2012 Apr; 12(4):307-14. PubMed ID: 21831253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
